Skip to content
DataLookout
Menu

NCT07439120

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 26 words
    • Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2026
    • Interventions: ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 (Drug) to ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 (Drug)
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2, 2026 to Apr 13, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Adeverse Events
Timeframe: From enrolment to 4 weeks after the first dose

Secondary (3)

PK Parameters
Biodistribution
Radiation Dosimetry

Arms and interventions

⁶⁸Ga/¹⁷⁷Lu-BRP-020063 Treatment ArmExperimental

Drugs: ⁶⁸Ga/¹⁷⁷Lu-BRP-020063

Sites

1 site in 1 country

  • Shanghai General HospitalShanghai, China